Researchers assessed the efficacy of a natalizumab 6-week dosing schedule in patients with multiple sclerosis who received natalizumab 4-week dosing without relapse for 12 or more months.
This was a retrospective cohort study that compared the risk of dementia in young patients with traumatic compared with spontaneous intracerebral hemorrhage.
Study investigators sought to determine whether acute treatment with rimegepant decreases analgesic or antiemetic use in people with migraine.
Efgartigimod may be an effective and well-tolerated treatment option for patients with myasthenia gravis.
Researchers presented their study results comparing headache education with mindfulness-based stress reduction for patients with migraine at the AAN 2021 Virtual Annual Meeting,
At the AAN 2021 Virtual Annual Meeting, investigators presented their study findings comparing plasma neurofilament light (NfL) and T-tau levels in predicting cognitive decline.
This post-hoc analysis detailed the effects of ADS-5102 on ON time and dyskinesia in patients with Parkinson Disease.
During the AAN 2021 Virtual meeting, researchers presented their study on infective endocarditis and the rate of acute ischemic stroke in patients with and without subarachnoid hemorrhage.
In an abstract presented at AAN 2021, researchers described the effect of disease-modifying therapies on COVID-19 severity in patients with COVID-19 and multiple sclerosis.
In an abstract presented at AAN 2021, researchers demonstrated the use of von Willebrand Factor as a biomarker of traumatic brain injury.
